Camurus ABCAMRF 81 Debt-to-Equity is 0.03 as of Mar. 2026, which is at its 10-year median of 0.03. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $83.45 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 965 Biotechnology companies, Camurus AB ranks better than 81.35% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Camurus AB's Debt-to-Equity or its related term are showing as below:
CAMRF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.06
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Camurus AB was 0.06. The lowest was 0.01. And the median was 0.03.
CAMRF's Debt-to-Equity is ranked better than 81.35% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs CAMRF: 0.03
Camurus AB (OTCPK:CAMRF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Camurus AB Debt-to-Equity Related Terms
Camurus AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Camurus AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Camurus AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Camurus AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Camurus AB and its competitors. This is near median its historical median of 0.03. Over the past decade, Camurus AB's Debt-to-Equity has ranged from 0.01 to 0.06. According to the industry distribution chart, Camurus AB ranks #180 out of 965 companies in the Biotechnology industry, placing it in the top 18.7%.
Is Camurus AB's Debt-to-Equity too high?
Camurus AB's current Debt-to-Equity of 0.03 is near median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.06. The Biotechnology industry median Debt-to-Equity is 0.16. Camurus AB's value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Camurus AB ranks #180 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #180 out of 965 companies for Debt-to-Equity. This places Camurus AB in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Camurus AB's value of 0.03 is 81.3% below this benchmark. Historically, Camurus AB's own Debt-to-Equity has ranged from 0.01 to 0.06 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Camurus AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Debt-to-Equity is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.45, compared to a current price of $60.00 — trading 28.1% below its estimated fair value. The current Debt-to-Equity is 0.03, which is near median its 10-year median of 0.03 and 81.3% below the Biotechnology industry median of 0.16. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $60.00 is trading 28.1% below its estimated GF Value™ of $83.45.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Debt-to-Equity: 0.03 (near median its 10-year median of 0.03)
GF Value™: $83.45 vs. price of $60.00 (28.1% below fair value)
Industry Position: 81.3% below the Biotechnology median (#180 of 965)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
